PubMed Health⌕ Search

PubMed · 12021523

Blunted nocturnal blood pressure decrease and left-ventricular mass in hypertensive hemodialysis patients.

Abstract

Left-ventricular hypertrophy (LVH) represents a frequent complication in hemodialysis (HD) patients. Hypertension is a well-known risk factor of cardiac morbidity which is present in 2 of 3 patients: among them about 60% have a blunted nocturnal decrease of blood pressure (BP). Although some large studies on essential hypertensives have documented that non-dipper patients have a higher number of cardiac events and a higher left ventricle (LV) mass than dipper ones, conflicting results have been reported for dialysis patients. Therefore, the aim of our study was to assess differences in LV mass between dipper and non-dipper hypertensive HD patients. We studied 66 patients with 24-hour ambulatory BP monitoring performed on HD and on inter-HD day. They were classified as dipper when a decrease of at least 10% of nocturnal systolic blood pressure on the inter-HD day was present. Echocardiography and bioimpedance were performed. 29% of the patients were classified as dippers and 71% as non-dippers. The 48-hour systolic and diastolic BP were not significantly different between the two groups (SBP: dipper = 144 +/- 12.9 mm Hg, non-dipper = 149 +/- 17.8 mm Hg; DBP: dipper = 80 +/- 9.9 mm Hg, non-dipper = 81 +/- 10.6 mm Hg). LV mass index (LVMi) did not differ between the two groups (dipper = 143.1 +/- 40.7 g/m(2); non-dipper = 159.4 +/- 46.3 g/m(2)). No differences were reported between dipper and non-dipper patients regarding extracellular water distribution (ECW: 48.1 +/- 7.7 vs. 49.8 +/- 10.8%). SBP night/day ratio and 48-hour SBP were not correlated to LVMi. A strong correlation was reported between ECW% and LVMi (r = 0.53, p < 0.001). In conclusion, 2 of 3 hypertensive HD patients are non-dipper, and this condition does not seem to be associated with significant differences in 48-hour blood pressure and LV mass. Volume overload appears to be the main independent determinant of LVH in these patients.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Riccardo M Fagugli, Giuseppe Quintaliani, Paolo Pasini, Giovanni Ciao, Beatrice Cicconi, Franca Pasticci, Umberto Buoncristiani. 2002. Blunted nocturnal blood pressure decrease and left-ventricular mass in hypertensive hemodialysis patients.. https://doi.org/10.1159/000057608

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Protective effect of anti-hypertensive treatment on cognitive function in essential hypertension: analysis of published clinical data.

Hypertension is a risk factor for stroke and may also contribute to the development of vascular cognitive impairment (VCI) and vascular dementia (VaD). Cognitive complications of hypertension and the influence of anti-hypertensive treatment were underestimated until recently. In this paper, trials investigating the effect of anti-hypertensive treatment on cognitive function were evaluated. Analysis of these studies revealed that until approximately 1990-1995 investigations have assessed primarily if anti-hypertensive treatment impaired cognitive function. Only more recent studies have investigated positive effects on cognition of anti-hypertensive medication. Drugs more extensively evaluated were diuretics, beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, sartanes and Ca(2+) channel blockers. Available studies have confirmed that elevated diastolic blood pressure or pulse pressure and isolated systolic hypertension play an important role in the development of cognitive impairment. Randomized placebo-controlled trials have provided evidence that reduction of hypertension safely and effectively decreases morbidity and mortality rates and cognitive complications of hypertension. Ca(2+) channel blockers and ACE inhibitors have been shown to be effective and probably better than diuretics and beta-blockers on cognitive domains of hypertension. More extensive investigations could contribute to establishing optimal choice and drug dosage for the treatment of cognitive complications of hypertension.

Antihypertensive Agents↗

Coronary artery disease.

SUMMARY: Prevention is equivalent to causal treatment of cardiovascular disease. Nowadays, guidelines are elaborated on the basis of large-scale long-term intervention studies and structured meta-analyses. This review attempts a synopsis of guidelines of the American and German Heart Associations. For secondary prevention, smoking cessation, blood pressure treatment, dietary lipid management, aerobic activity, correct body weight, Mediterranean diet, treatment of diabetes to a HbA1c of 7%, ingestion of marine w-3 fatty acids (1 g / day), platelet inhibitors, lipid-lowering agents (statins), beta-blockers and ACE-inhibitors are established. In primary prevention pharmaceutical agents are not incorporated, but all non-pharmacological approaches are being recommended. The guidelines mentioned are based on unequivocal evidence, risk-benefit and cost-benefit ratios are good, nevertheless implementation remains a serious problem. Primary and secondary prevention are already giving way to risk-adapted prevention, based on an individual assessment of a person's cardiovascular risk.

Antihypertensive Agents↗